On the basis of above clinical researches, PD-1 inhibitors as monotherapy have been approved by the US Food and Drug Administration and the European Medicines Agency to treat some pretreated R/M HNSCC. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.